Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs (Q37682555)

22 August 2017

1 reference

title

Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs (English)

1 reference

22 August 2017

James R LaSalle

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

22 August 2017

published in

Postgraduate Medicine

1 reference

22 August 2017

volume

122

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

144-152

1 reference

Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Racial and ethnic differences in glycemic control of adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Clinical significance, pathogenesis, and management of postprandial hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Implementing treatment guidelines for type 2 diabetes in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

Minutes of The 43rd General Assembly of The European Association for The Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.01.2108

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.01.2108

1 reference

22 August 2017

1 reference